BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and ...
Vyne Therapeutics Inc. has selected a development candidate, VYN-202, for its oral BD2-selective bromodomain and extra-terminal (BET) inhibitor program for the treatment of immuno-inflammatory ...
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback